Winston Abara

Dr. Winston Abara


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 April 2022 in The Lancet Infectious Diseases
Verified
Journal Article
Closed access
WAWinston Abara
Winston Abara
KBKyle T Bernstein
Kyle T Bernstein
FLFelicia M T Lewis
Felicia M T Lewis
JSJulia A Schillinger
Julia A Schillinger
KFKristen Feemster
Kristen Feemster
RKRobert D Kirkcaldy
Robert D Kirkcaldy

22 July 2016 in PLOS ONE
Verified
Journal Article
Open access
PDF file
WAWinston Abara
Winston Abara
KHKristen L. Hess
Kristen L. Hess
RFRobyn Neblett Fanfair
Robyn Neblett Fanfair
KBKyle T. Bernstein
Kyle T. Bernstein
GPGabriela Paz-Bailey
Gabriela Paz-Bailey
Globally, men who have sex with men (MSM) are disproportionately burdened with syphilis. This review describes the published literature on trends in syphilis infections among MSM in the US and Western Europe from 1998, the period with the fewest syphilis infections in both geographical areas, onwards. We also describe disparities in syphilis trends among various sub-populations of MSM. We searched electronic databases (Medline, Embase, Global Health, PsychInfo, CAB Abstracts, CINAHL, Sociological Abstracts, Web of Science, Cochrane Library, and LILACS) for peer-reviewed journal articles that were published between January 2004 and June 2015 and reported on syphilis cases among MSM at multiple time points from 1998 onwards. Ten articles (12 syphilis trend studies/reports) from the US and eight articles (12 syphilis trend studies/reports) from Western Europe were identified and included in this review. Taken together, our findings indicate an increase in the numbers and rates (per 100,000) of syphilis infections among MSM in the US and Western Europe since 1998. Disparities in the syphilis trends among MSM were also noted, with greater increases observed among HIV-positive MSM than HIV-negative MSM in both the US and Western Europe. In the US, racial minority MSM and MSM between 20 and 29 years accounted for the greatest increases in syphilis infections over time whereas White MSM accounted for most syphilis infections over time in Western Europe. Multiple strategies, including strengthening and targeting current syphilis screening and testing programs, and the prompt treatment of syphilis cases are warranted to address the increase in syphilis infections among all MSM in the US and Western Europe, but particularly among HIV-infected MSM, racial minority MSM, and young MSM in the US.

1 February 2023 in JAMA Network Open
Verified
Journal Article
Closed access
PDF file
WAWinston Abara
Winston Abara
JGJulianne Gee
Julianne Gee
PMPaige Marquez
Paige Marquez
JWJared Woo
Jared Woo
TMTanya R. Myers
Tanya R. Myers
DSDavid K. Shay
David K. Shay
Guillain-Barré syndrome (GBS) is a rare, immune-mediated neurologic disorder of the peripheral nervous system that is characterized by ascending weakness and paralysis.1 Between 3000 and 6000 cases of GBS (1-2 cases/100 000 persons) are diagnosed annually in the United States.2,3 Although the etiology of GBS is unclear, molecular mimicry is thought to play a role in its pathogenesis.4 Autoimmune antibodies likely target epitopes on peripheral nerves, leading to neuronal demyelination and axonal damage.4 Production of these autoimmune antibodies may be triggered by an antecedent infection. Approximately two-thirds of patients with GBS report an antecedent gastrointestinal or respiratory infection within 3 weeks before symptom onset.5 Rarely, vaccination has been associated with GBS. The first epidemiological association was found in 1976, when an increased GBS risk was observed among persons who received the swine flu vaccine.6 Subsequently, an increased GBS risk was found after recombinant zoster vaccination.7 Associations between seasonal influenza vaccination and GBS have been inconsistently noted; some studies have shown a small increase in GBS risk among vaccinated persons while others have not.8,9

31 July 2024 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
WAWinston Abara
Winston Abara
RKRobert D Kirkcaldy
Robert D Kirkcaldy
KBKyle T Bernstein
Kyle T Bernstein
EGEboni Galloway
Eboni Galloway
ELEmily R Learner
Emily R Learner
There is no licensed vaccine against gonorrhea but Neisseria meningitidis serogroup B outer membrane vesicle-based vaccines, like MenB-4C, may offer cross-protection against gonorrhea. This systematic review and meta-analysis synthesized the published literature on MenB-4C vaccine effectiveness against gonorrhea. We conducted a literature search of electronic databases (PubMed, Medline, Embase, Global Health, Scopus, Google Scholar, CINAHL, and Cochrane Library) to identify peer-reviewed papers, published in English, from 1/1/2013–7/12/2024 that reported MenB-4C vaccine effectiveness estimates against gonorrhea and gonorrhea/chlamydia co-infection, and the duration of MenB-4C vaccine-induced protection. We estimated pooled MenB-4C vaccine effectiveness (≥1 dose) against gonorrhea using the DerSimonian-Laird random effects model. Eight papers met our eligibility criteria. Receipt of ≥1 dose of MenB-4C vaccine was 23%–47% effective against gonorrhea. Two doses of MenB-4C vaccine were 33–40% effective against gonorrhea and one dose of MenB-4C vaccine was 26% effective. MenB-4C vaccine effectiveness against gonorrhea/chlamydia co-infection was mixed with two studies reporting effectiveness estimates of 32% and 44%, and two other studies showing no protective effect. MenB-4C vaccine effectiveness against gonorrhea was comparable in people living with HIV (44%) and people not living with HIV (23%–47%). Pooled MenB-4C vaccine effectiveness (≥1 dose) against gonorrhea was 32.4%. One study concluded that MenB-4C vaccine effectiveness against gonorrhea may wane approximately 36 months post-vaccination. MenB-4C vaccine is moderately effective against gonorrhea in various populations. Prospective clinical trials that assess the efficacy of MenB-4C against gonorrhea, gonorrhea/chlamydia co-infection, and duration of protection are warranted to strengthen this evidence.

25 January 2019 in MMWR. Morbidity and Mortality Weekly Report
Verified
Journal Article
Closed access
WAWinston Abara
Winston Abara
MCMelissa G. Collier
Melissa G. Collier
AMAnne Moorman
Anne Moorman
DBDanae Bixler
Danae Bixler
JJJefferson Jones
Jefferson Jones
SBSridhar V. Basavaraju
Sridhar V. Basavaraju
The number and proportion of increased risk donors have increased since 2010, likely because of the epidemic of opioid overdose deaths. Compared with standard risk donors, increased risk donors were significantly more likely to have hepatitis B virus and hepatitis C virus infection. Rates of nucleic acid testing have reached nearly 100%.

31 October 2013 in Journal of Religion and Health
Verified
Journal Article
Closed access
PDF file
WAWinston Abara
Winston Abara
JCJason D. Coleman
Jason D. Coleman
AFAmanda Fairchild
Amanda Fairchild
BGBambi Gaddist
Bambi Gaddist
JWJacob White
Jacob White